Your browser doesn't support javascript.
loading
Dosimetric and radiobiologic comparison of 103Pd COMS plaque brachytherapy and Gamma Knife radiosurgery for choroidal melanoma.
Gorovets, Daniel; Gagne, Nolan L; Melhus, Christopher S.
Afiliação
  • Gorovets D; Department of Radiation Oncology, Tufts University School of Medicine, Boston, MA.
  • Gagne NL; Department of Radiation Oncology, Tufts University School of Medicine, Boston, MA.
  • Melhus CS; Department of Radiation Oncology, Tufts University School of Medicine, Boston, MA. Electronic address: cmelhus@tuftsmedicalcenter.org.
Brachytherapy ; 16(2): 433-443, 2017.
Article em En | MEDLINE | ID: mdl-28161431
ABSTRACT

PURPOSE:

Plaque brachytherapy (BT) and Gamma Knife radiosurgery (GKRS) are highly conformal treatment options for choroidal melanoma. This study objectively compares physical dose and biologically effective dose (BED) distributions for these two modalities. METHODS AND MATERIALS Tumor and organ-at-risk (OAR) dose distributions from a CT-defined reference right eye were compared between 103Pd COMS (Collaborative Ocular Melanoma Study Group) plaques delivering 70 Gy (plaque heterogeneity corrected) over 120 h to the tumor apex and GKRS plans delivering 22 Gy to the 40% isodose line for a representative sample of clinically relevant choroidal melanoma locations and sizes. Tumor and OAR biologically effective dose-volume histograms were generated using consensus radiobiologic parameters and modality-specific BED equations.

RESULTS:

Published institutional prescriptive practices generally lead to larger tumor and OAR physical doses from COMS BT vs. GKRS. Radiobiologic dose conversions, however, revealed variable BEDs. Medium and large tumors receive >1.3 times higher BEDs with COMS BT vs. GKRS. OAR BEDs have even greater dependence on tumor size, location, and treatment modality. For example, COMS BT maximum BEDs to the optic nerve are lower than from GKRS for large anterior and all posterior tumors but are higher for anterior small and medium tumors.

CONCLUSIONS:

BT and GKRS for choroidal melanoma have different physical dose and BED distributions with potentially unique clinical consequences. Using published institutional prescriptive practices, neither modality is uniformly favored, although COMS BT delivers higher physical doses and BEDs to tumors. These results suggest that lowering the physical prescription dose for COMS BT to more closely match the BED of GKRS might maintain equivalent tumor control with less potential morbidity.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Paládio / Radioisótopos / Braquiterapia / Neoplasias da Coroide / Radiocirurgia / Melanoma Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Paládio / Radioisótopos / Braquiterapia / Neoplasias da Coroide / Radiocirurgia / Melanoma Idioma: En Ano de publicação: 2017 Tipo de documento: Article